Versantis

About

Versantis is a spin-off company from ETH Zürich . The company develops transformative orphan drugs in liver and pediatric diseases with the goal to revolutionize the critical care of cirrhosis decompensations and neonatal hyperammonemic crises. The lead candidate, VS-01 , is a proprietary first-line treatment in clinical-stage for acute liver diseases able to simultaneously support the failing liver, brain, and kidney.